Virpax Pharmaceuticals, Inc., a Delaware-incorporated company listed on The Nasdaq Capital Market under the trading symbol VRPX, has received a delisting notice from Nasdaq. The notice, dated October 3, 2024, was issued after the company failed to meet the minimum stockholders' equity requirement of $2,500,000 as stipulated by Nasdaq Listing Rule 5550(b). Despite submitting a compliance plan and being granted an extension until September 30, 2024, Virpax Pharmaceuticals was unable to regain compliance within the allotted timeframe. The company has been informed that unless it appeals, trading of its common stock will be suspended starting October 14, 2024, followed by the filing of a Form 25-NSE to formally delist the stock. Virpax Pharmaceuticals plans to request a hearing with the Nasdaq Hearings Panel, which could delay the delisting process until the conclusion of the hearing and any further extensions granted. However, there is no guarantee that the Panel will grant an additional extension or that the company will be able to meet the continued listing requirements in the future.

Virpax Pharmaceuticals, Inc., a Delaware-incorporated company listed on The Nasdaq Capital Market under the trading symbol VRPX, has received a delisting notice from Nasdaq. The notice, dated October 3, 2024, was issued after the company failed to meet the minimum stockholders' equity requirement of $2,500,000 as stipulated by Nasdaq Listing Rule 5550(b). Despite submitting a compliance plan and being granted an extension until September 30, 2024, Virpax Pharmaceuticals was unable to regain compliance within the allotted timeframe. The company has been informed that unless it appeals, trading of its common stock will be suspended starting October 14, 2024, followed by the filing of a Form 25-NSE to formally delist the stock. Virpax Pharmaceuticals plans to request a hearing with the Nasdaq Hearings Panel, which could delay the delisting process until the conclusion of the hearing and any further extensions granted. However, there is no guarantee that the Panel will grant an additional extension or that the company will be able to meet the continued listing requirements in the future.